Cipher Pharmaceuticals Inc
TSX:CPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cipher Pharmaceuticals Inc
Selling, General & Administrative
Cipher Pharmaceuticals Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
Selling, General & Administrative
-$16.3m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
6%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Selling, General & Administrative
-$3.4B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-2%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Selling, General & Administrative
-CA$105.4m
|
CAGR 3-Years
39%
|
CAGR 5-Years
31%
|
CAGR 10-Years
-25%
|
|
|
Cronos Group Inc
TSX:CRON
|
Selling, General & Administrative
-$70.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
-46%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Selling, General & Administrative
-$46m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
-98%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Selling, General & Administrative
-CA$124.1m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-30%
|
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.
See Also
What is Cipher Pharmaceuticals Inc's Selling, General & Administrative?
Selling, General & Administrative
-16.3m
USD
Based on the financial report for Dec 31, 2025, Cipher Pharmaceuticals Inc's Selling, General & Administrative amounts to -16.3m USD.
What is Cipher Pharmaceuticals Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
6%
Over the last year, the Selling, General & Administrative growth was -33%. The average annual Selling, General & Administrative growth rates for Cipher Pharmaceuticals Inc have been -53% over the past three years , -21% over the past five years , and 6% over the past ten years .
